| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Opt In/Out Tag | Opt-In or -Out | Option Holder | Option Duration | Implications for Financial Consideration | Deal Date | R&D | Client | Licensee Category | Stage at Signing | Deal Source | Upfront Cash ($M) | Deal Size ($M) | Maximum Share (%) | Deal | Territory | Deal Subject | Deal Type | Disease | Indication | Technology | Sub-Technology | Upfront Equity ($M) | Contingent Equity ($M) | R&D Support ($M) | FTE Rate ($M) | Loan ($M) | Dev / Reg Milestones ($M) | Other Milestones ($M) | Total Precommercial Payments ($M) | Sales Milestones ($M) | EFR$200M (%) | EFR$500M (%) | EFR$1B (%) | Marketing Fee (%) | Transfer Price (%) | Manufacture Cost + (%) | Profit Split (%) | Financial Term Explanations |
2 | Tag | Out | Either party | Phase III done | 10-20% royalty, depending on stage & party | 8/2009 | Emergent BioSolutions, Trubion | Abbott, Facet | Top Pharma | Phase I | FOIA | 20.00 | 206.50 | 50.00 | Deal | Worldwide | TRU-016 (CD37 modulator) for for chronic lymphocytic leukemia (CLL) | Co-Development, Co-Promotion, Equity, License, Termination | Cancer | Leukemia | Recombinant DNA | 10.00 | 0.28 | 128.50 | 48.00 | 206.50 | 50.00 | 10-20% royalty if Trubion opts out of co-dev, depending on stage at opt-out | |||||||||||
3 | Tag | Out | Either party | Any | 20-25% royalty if Ariad; 40% PS if Merck | 7/2007 | Takeda, ARIAD Pharmaceuticals | Merck | Top Pharma | Phase II | FOIA | 75.00 | 927.00 | 50.00 | Deal | Worldwide | Taltorvic (ridaforolimus mTOR inhibitor) for sarcoma & solid tumors | Co-Development, Co-Promotion, License, Loan, Supply, Termination | Cancer | Broad Focus Cancer, Solid Tumors | Synthetics | Small Molecule | 0.28 | 200.00 | 88.50 | 363.50 | 727.00 | 200.00 | 15.00 | 15.00 | 16.00 | 50.00 | $200M loan for Ariad share of dev costs above $150M | $88.5M sarcoma | 5050 US PS for sacroma & other indications until opt-out | ||||||
4 | Tag | Out | Either party | Any | 10-15% royalty, depending on party & stage | 7/2007 | Roche, Genentech | Ipsen, Tercica | Mid Tier Pharma | Preclinical | FOIA | 18.00 | 12.00 | Deal | Worldwide | Growth hormone & IGF-1 combination product for short stature | Co-Development, Co-Promotion, Equity, License, Option | Endocrinological & Metabolic | Growth Hormone Disorders | Recombinant DNA | 4.00 | 9.00 | 5.00 | 18.00 | 12.00 | 12.00 | 12.00 | 25.00 | 50.00 | GNE purchases 708.6K Tercica shares | Add'l $4M eq purchase if GNE extends opt-in period, plus $5M eq at approval | 12% royalty to GNE if GNE never opts-in | 50/50 PS for Short Stature and AGHD Indications after GNE opt-in, but drops to 33.3% if GNE pays $10M to have tie-breaking vote | |||||||||
5 | Tag | Out | Either party | Any | 3-14% royalty, depending on stage | 8/2006 | Infinity Pharmaceuticals | AstraZeneca, MedImmune | Top Pharma | Phase I, Discovery | FOIA | 70.00 | 500.00 | 50.00 | Deal | Worldwide | IPI-504 (hsp90 inhibitor) and Hedgehog cell-signaling pathway for cancer | Co-Development, Co-Promotion, License, Termination | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | 140.00 | 140.00 | 350.00 | 150.00 | 50.00 | $75M for each of Hedgehog & Hsp90 Products | $140M for Hedgehog Products | $140M for Hsp90 Products | |||||||||||
6 | Tag | Out | Either party | Any | 5-12% royalty, depending on stage | 7/2006 | Alnylam | Merck | Top Pharma | Discovery | FOIA | 84.50 | 50.00 | Deal | Worldwide | RNAi for nine non-druggable targets | Co-Development, Co-Promotion, License, Option, Research, Restatement, Termination | Unlimited | Oligonucleotides | RNAi | 0.49 | 41.00 | 43.50 | 84.50 | 10.00 | 11.40 | 13.00 | 50.00 | 10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products | ||||||||||
7 | Tag | Out | Either party | Any | 1.5-6% royalties & milestones depending on stage | 7/2006 | ChemDiv | Clinical Data, Avalon Pharmaceuticals | Other Biotech | Discovery | FOIA | 0.20 | 50.00 | Deal | Worldwide | Screening of combichem library against drug targets | Co-Development, License, Research | Unlimited | Screening, Synthetics | Combinatorial | 0.20 | 0.20 | 50.00 | ||||||||||||||||
8 | Tag | Out | Either party | Any | reduced royalty & milestones TBD | 1/2006 | Nycomed Pharma, Takeda, Bradley Pharmaceuticals | Medigene | Other Biotech | Filed | FOIA | 5.00 | 69.50 | 10.00 | Deal | NAFTA | Polyphenon ointment for genital warts in US | Co-Development, License | Dermatologic, Infectious-Viral | Actinic Keratosis, Other Infectious-Viral | Natural Product | 14.00 | 20.50 | 39.50 | 30.00 | 10.00 | 10.00 | 10.00 | |||||||||||
9 | Tag | Out | Either party | Any | Independent 2-22% royalty, depending on stage | 9/2005 | Facet, Abbott, AbbVie, PDL BioPharma | Biogen | Major Biotech | Phase II, Orphan Indication | FOIA | 40.00 | 520.00 | 50.00 | Deal | Worldwide | Zinbryta (daclizumab) for multiple sclerosis, M200 (volociximab) & HuZAF (fontolizumab) | Co-Development, Co-Promotion, Equity, License, Supply | Autoimmune/Inflammatory, Cancer, Central Nervous System | Broad Focus Autoimmune/Inflammatory, Multiple Sclerosis, Solid Tumors | Monoclonals | Humanized Abs | 5.00 | 0.25 | 85.00 | 240.00 | 370.00 | 50.00 | 12.00 | 13.60 | 16.80 | 15.00 | 50.00 | $85M in dev/reg milestones for IL-2R or INFy for 1st indication | $80M for each of 2nd & 3rd IL-2R or INFy indications, plus $40M for each of 2nd &3rd A5B1 indications | 50/50 PS in NA and EU | ROW Royalty of 12-20% | |||||
10 | Tag | Out | Either party | Any | 3-12% royalty, depending on stage | 5/2005 | Lexicon Pharmaceuticals | Schering-Plough, Merck, Organon | Top Pharma | Discovery | FOIA | 22.50 | 82.50 | 50.00 | Deal | Worldwide | Drug targets from genes that encode secreted proteins & antibody targets | Co-Development, License, Research, Termination | Unlimited | Genomics, Transgenics | Gene Expression | 50.00 | 0.30 | 10.00 | 82.50 | 50.00 | 3-12% royalty on Opt-out Products, depending on stage of dev at opt-out | ||||||||||||
11 | Tag | Out | Either party | Any | 1.5-9.5% royalty, depending on stage/party | 5/2005 | Xoma | Novartis, Chiron | Top Pharma | Discovery | FOIA | 10.00 | 60.00 | 30.00 | Deal | Worldwide | CD40, M-CSF, MN & EphB3 Mabs for cancer | Co-Development, Co-Promotion, License, Loan, Option, Research, Restatement, Termination | Cancer | Broad Focus Cancer | Monoclonals | Human Abs | 0.28 | 50.00 | 60.00 | 30.00 | Xoma funds 30% Chiron 70% | $50M loan facility (see separate contract) | 22.5-30% PS to Xoma, with lower rate paid until $15M differential utilized (or reduced via milestones accomplished) | ||||||||||||
12 | Tag | Out | Either party | Any | 1.75-9% royalty, depending on stage | 2/2005 | Mirati Therapeutics, MethylGene | EnVivo Pharmaceuticals | Other Biotech | Discovery | FOIA | 0.50 | 1.70 | 50.00 | Deal | Worldwide | HDAC (histone deacetylase) inhibitors for Huntington's & neuro diseases | Co-Development, Co-Promotion, License, Research, Termination, Warrant | Central Nervous System | Alzheimer's Disease, Other Central Nervous System, Parkinson's Disease | Genomics, Screening, Synthetics | Gene Expression, Small Molecule | 1.20 | 0.15 | 1.70 | 50.00 | 52.5K warrant shares of MethylGene common | $600K for 4 MethylGene FTEs @ $150K/FTE, plus first $600K for Alzheimer's program (all other costs shared 50/50) | ||||||||||||
13 | Tag | Out | Either party | Any | royalty-free (but sublicense rev sharing) | 11/2004 | Cambridge Antibody Technology | AstraZeneca | Top Pharma | Discovery | FOIA | 305.00 | 21.00 | Deal | Worldwide | Human antibodies for inflammation | Co-Development, Co-Promotion, Equity, License, Research | Autoimmune/Inflammatory | Broad Focus Autoimmune/Inflammatory | Monoclonals | Human Abs | 105.00 | 0.22 | 100.00 | 205.00 | 100.00 | 19.00 | 19.00 | 19.00 | 75M pounds sterling | |||||||||
14 | Tag | Out | Either party | Phase II data | 0-8% royalty, depending on stage | 7/2004 | Seattle Genetics | Applera, Quest Diagnostics, Celera | Mid Tier Pharma | Discovery | FOIA | 18.00 | 50.00 | Deal | Worldwide | ADC technology for novel cell surface proteins to treat cancer | Co-Development, Co-Promotion, License, Option, Research | Cancer | Broad Focus Cancer | Monoclonals | Conjugates | 0.28 | 3.00 | 3.00 | 15.00 | 50.00 | 0-8% royalty by Continuing party after opt-out, depending on stage of dev at opt-out | ||||||||||||
15 | Tag | Out | Either party | Phase IIb data | $25M milestones & 10-15% royalty | 6/2004 | Alnylam | Merck | Top Pharma | Discovery | FOIA | 3.00 | 33.50 | 50.00 | Deal | Worldwide | RNAi VEGF for ocular diseases | Co-Development, Co-Promotion, License, Research, Termination | Ophthalmic | Broad Focus Ophthalmic | Oligonucleotides | RNAi | 0.49 | 30.50 | 33.50 | 10.40 | 11.40 | 13.00 | 50.00 | ||||||||||
16 | Tag | Out | Either party | Any | 3-25% royalty, depending on stage of dev | 12/2003 | Lilly, UroGene, SGX Pharmaceuticals | Pierre Fabre | Mid Tier Pharma | Discovery | FOIA | 25.00 | Deal | Europe | Inhibitors of RON tyrosine kinase for bladder cancer in Europe | Co-Development, License, Research, Termination | Cancer | Bladder | Genomics, Synthetics | Pharmacogenomics, Small Molecule | 0.20 | 25.00 | 25.00 | 25.00 | 50/50 cost sharing | ||||||||||||||
17 | Tag | Out | Either party | Any | royalty-free license vs 50% PS | 12/2003 | ViaCell | Amgen | Major Biotech | Preclinical | FOIA | 30.00 | 50.00 | Deal | Worldwide | Stem cell based cell therapy | Co-Development, Equity, License, Option, Warrant | Unlimited | Cell Therapy - Stem Cells/Factors | 20.00 | 10.00 | 50.00 | 50/50 PS on Collaboration Products | ||||||||||||||||
18 | Tag | Out | Either party | Any | $8.5M milestones plus 2-6% royalty | 10/2003 | Bristol-Myers Squibb, Medarex | Clinical Data, Avalon Pharmaceuticals | Other Biotech | Discovery | FOIA | 50.00 | Deal | Worldwide | Human antibodies to selected cancer targets | Co-Development, License, Research | Cancer | Broad Focus Cancer | Monoclonals | Human Abs | 50.00 | 2-6% royalty if one party opts-out, depending on stage at opt-out | |||||||||||||||||
19 | Tag | Out | Either party | Any | 2% lower royalty & no co-promotion | 8/2002 | Rigel Pharmaceuticals | Daiichi Sankyo | Japanese Pharma | Discovery | FOIA | 1.00 | 29.04 | 6.00 | Deal | Worldwide | Protein degradation of MDM2 ubiquitin ligase for cancer therapy | Co-Development, Co-Promotion, License, Option, Research | Cancer | Broad Focus Cancer | Screening, Synthetics | Small Molecule | 5.04 | 0.28 | 20.00 | 3.00 | 29.04 | 4.00 | 4.00 | 4.00 | 6 FTEs/yr for 3 yrs @ $275K, $280K & $285K/FTE/yr | 4% royalty, but 6% if Rigel co-dev | Add'l $3M if Rigel co-dev | ||||||||
20 | Tag | Out | Either party | Any | 3% add'l royalty until 65% cost recovered | 6/2002 | Applera, Quest Diagnostics, Celera | Abbott | Top Pharma | Diagnostic | FOIA | 50.00 | Deal | Worldwide | In vitro diagnostic products and services | Co-Development, Co-Promotion, License, Research, Termination | Cancer | Diagnostics | DNA Probes | 50.00 | |||||||||||||||||||
21 | Tag | Out | Either party | Any | 0.5-4% royalty, depending on IP | 1/2002 | Seattle Genetics | Danisco, Genencor | Other Biotech | Lead Molecule, Discovery | FOIA | 1.00 | 5.50 | 50.00 | Deal | Worldwide | ADEPT technology for cancer prodrugs | Co-Development, Equity, License, Research | Cancer | Broad Focus Cancer, Melanoma | Monoclonals | 3.00 | 0.20 | 1.50 | 6.00 | 50.00 | 3-4% royalty if SGEN opts-out of co-dev | ||||||||||||
22 | Tag | Out | Either party | Any | 1-2% royalty, depending on party | 11/2001 | Ionis Pharmaceuticals | Achieve Life Science, OncoGenex Pharmaceuticals | Other Biotech | Preclinical | FOIA | 0.50 | 0.50 | 65.00 | Deal | Worldwide | OGX-011 (antisense inhib of clusterin) for prostate cancer | Co-Development, License, Termination | Cancer | Prostate | Oligonucleotides | Antisense/Triple helix | 0.33 | 0.50 | 65.00 | ||||||||||||||
23 | Tag | Out | Either party | Any | by stage: 2.5-25% PS plus 1-5% royalty | 10/2001 | Athersys | Johnson & Johnson, 3-Dimensional Pharmaceuticals | Top Pharma | Discovery | FOIA | 50.00 | Deal | Worldwide | Small molecules to GPCR targets (VR1, MCHR1, CXCR3, Glucagon rec) | Co-Development, License, Research | Unlimited | Genomics, Screening | Gene Expression, Proteomics | 0.25 | 50.00 | ||||||||||||||||||
24 | Tag | Out | Either party | Phase IIb data | If appvd: 300% of share plus 4% lower PS | 7/2001 | Lilly, ICOS | Biogen | Major Biotech | Phase I | FOIA | 8.00 | 111.50 | 50.00 | Deal | Worldwide | Oral LFA-1 (Leukocyte Function Antigen-1) antagonists for inflammation | Co-Development, Co-Promotion, License, Loan, Supply, Termination | Autoimmune/Inflammatory | Broad Focus Autoimmune/Inflammatory | Synthetics | Small Molecule | 20.00 | 30.00 | 21.00 | 79.00 | 32.50 | 50.00 | 50.00 | $20M forgivable loan, based on clinical milestones | |||||||||
25 | Tag | Out | Either party | Any | $8.5M milestones plus 3-5% royalty | 6/2001 | Amgen, deCODE Genetics | Medarex, Bristol-Myers Squibb, Genmab | Top Pharma | Discovery | FOIA | 17.00 | 50.00 | Deal | Worldwide | Fully human antibodies from genomic data | Co-Development, License, Research | Unlimited | Genomics, Monoclonals | Human Abs, Pharmacogenomics | 8.50 | 8.50 | 15.00 | 3.50 | 4.40 | 4.70 | 50.00 | Licensee pays 3-5% royalty on unilateral products | Licensee pays $8.5M in dev/reg milestones for each add'l unilateral product | Licensee pays $8.5M in dev/reg milestones for 1st unilateral product | |||||||||||
26 | Tag | Out | Either party | Phase III done | $8.5M milestones plus 3-5% royalty | 2/2001 | Medarex, Bristol-Myers Squibb, GenPharm | Seattle Genetics | Other Biotech | Discovery | FOIA | 22.50 | 50.00 | Deal | Worldwide | Human MAb to p97 (melanotransferrin) for treatment of melanoma | Co-Development, License, Research | Cancer | Melanoma | Monoclonals | Human Abs | 8.50 | 14.00 | 22.50 | 3.50 | 4.40 | 4.70 | 50.00 | 5% max royalty on Unilateral Products | $8.5M for first Unilateral Product | $14M for add'l Unilateral Products | ||||||||||
27 | Tag | Out | Either party | Any | 5% royalty on Independent Product | 12/1999 | Novartis, Chiron | PathoGenesis | Other Biotech | Discovery | FOIA | 50.00 | Deal | Worldwide | Combinatorial chemistry to discover novel anti-bacterials | Co-Development, License, Research | Infectious-Bacterial | Broad Focus Infectious-Bacterial | Screening, Synthetics | Combinatorial, Small Molecule | |||||||||||||||||||
28 | Tag | Out | Licensee | Phase I data | 5% royalty until dev cost recovered, then 1% | 11/2008 | Infinity Pharmaceuticals | Purdue Pharma | Mid Tier Pharma | Discovery | FOIA | 13.50 | 20.00 | Deal | NAFTA | FAAH (Fatty Acid Amide Hydrolase) for solid tumors in US | License, Research, Termination | Cancer | Solid Tumors | Synthetics | Small Molecule | 13.50 | 0.38 | 13.50 | 12.50 | 17.00 | 18.50 | $13.5M over 3 yrs @ $375K/FTE | |||||||||||
29 | Tag | Out | Licensee | Any | royalty-free and supply at cost +10% | 8/2004 | Palatin Technologies | Pfizer, King Pharmaceuticals | Top Pharma | Phase II | FOIA | 15.00 | 250.00 | 50.00 | Deal | Worldwide | PT-141 (melanocortin receptor agonist) sexual dysfunction in NAFTA & ROW | Co-Development, Co-Promotion, Equity, License, Warrant | Genitourinary/Gynecologic | Sexual Dysfunction | Peptides | 5.00 | 12.50 | 37.50 | 50.00 | 120.00 | 130.00 | 50.00 | $12.5M warrant | $27.5M cash & $10M eq for ED | $40M cash & $10M eq for other | 40% PS to Palatin in NAFTA to $400M, then 35% PS above; 50/50 in ROW | ||||||||||
30 | Tag | Out | Licensor | Phase I data | Reduced PS (50 to 26%) if KHK opt-out of co-dev | 6/2016 | Kyowa Hakko Kirin | Aevi Genomic Medicine | Other Biotech | Phase I, Orphan Indication | FOIA | 2.00 | 20.00 | 50.00 | Deal | NAFTA | Anti-LIGHT (TNFSF14 mAb) for severe pediatric onset IBD in NA | Co-Development, License, Option, Supply | Gastrointestinal | IBD - Other | Monoclonals | Human Abs | 0.35 | 18.00 | 20.00 | 10.00 | 50.00 | $2M on license exercise | equal sharing up to $17.5M aggergate, then all by Medgenics in Territory & EU | $150K-$350K/FTE | KHK pays 13% royalty to Medgenics on EU sales | 50/50 PS in NA if KHK co-develops; otherwise 74% PS to Medgenics | |||||||||||
31 | Tag | Out | Licensor | Phase II data | Reduced PS (25 to 15% floor) based on reduced cost | 3/2016 | Arcturus Therapeutics | Providence Therapeutics | Other Biotech | Discovery, Formulation | SEC Full | 0.50 | 0.50 | 25.00 | Deal | Worldwide | Individualized LUNAR delivery of mRNA vaccine for brain, breast and ovarian neoplasms | Co-Development, Joint Venture, License, Research | Cancer | Brain, Breast, Ovarian | Drug Delivery, Vaccines | Other | 0.35 | 0.50 | 25.00 | 25% PS to Arcturus (unless opt-out) | |||||||||||||
32 | Tag | Out | Licensor | Phase I data | 2x co-dev cost & 1-5% of Net Income | 5/2015 | Beryllium | ArQule | Other Biotech | Discovery | FOIA | 50.00 | Deal | Worldwide | Screening small molecules targeting PD-1 and PDL-1 | Co-Development, License, Research, Termination | Cancer | Broad Focus Cancer | Screening, Synthetics | Small Molecule | 0.33 | 50.00 | |||||||||||||||||
33 | Tag | Out | Licensor | Phase III data | reimb of add'l co-dev cost plus 10-13.5% royalty | 12/2014 | MacroGenics | Johnson & Johnson, Janssen | Top Pharma | Preclinical | FOIA | 50.00 | 700.00 | 30.00 | Deal | Worldwide | Duvortuxizumab (MGD011 humanized CD19 /CD3) for multiple B-cell malignancies | Co-Development, Co-Promotion, Equity, License, Option, Termination | Cancer | Leukemia, Lymphoma | Monoclonals | Bispecific | 75.00 | 0.28 | 210.00 | 215.00 | 550.00 | 150.00 | 10.00 | 10.00 | 10.00 | 30.00 | $210M for DLBCL (diffuse large B-cell lymphoma) | $215M for add'l indications | 30% PS in NA if MacroGenics pays 20% of Global Dev Costs | ||||||
34 | Tag | Out | Licensor | Phase II data | 6-12.5% royalty, depending on stage & sales | 11/2014 | Proteostasis Therapeutics | Astellas Pharma | Japanese Pharma | Discovery, Orphan Indication | FOIA | 408.80 | 12.50 | Deal | Worldwide | Protein folding platform to treat alpha-1 anti-trypsin deficiency via UPR modulation | Co-Development, Co-Promotion, Equity, License, Loan, Option, Research | Other/Miscellaneous | Genetic Disorders | Screening, Synthetics | Small Molecule | 5.00 | 5.80 | 0.33 | 56.00 | 66.80 | 342.00 | 5.50 | 6.00 | 6.75 | $5M equity via conversion of 7/14 note | 17.75 FTEs @ $325K/FTE | 5.5-7.5% if no co-dev; 6-12.5% if co-dev, depending on how far into clinical trials | ||||||||
35 | Tag | Out | Licensor | Phase III done | 50% US PS, less share of Selling Expenses | 4/2012 | Novartis, Endocyte | Merck | Top Pharma | Phase III | FOIA | 120.00 | 1,001.50 | 50.00 | Deal | Worldwide | Vintafolide (EC145) folate conjugate for lung & ovarian cancer | Co-Development, Co-Promotion, License, Option, Termination | Cancer | Lung, Ovarian | Synthetics | Small Molecule | 0.25 | 47.50 | 334.00 | 501.50 | 500.00 | 14.00 | 14.00 | 15.00 | 50.00 | Endocyte pays 75% of PROC (ovarian) Ph III plus 100% of Companion Diagnostic; Merck pays all other dev costs | 14-20% ex-US royalty | $47.5M for Ovarian (PROC) | $60M for Lung; $274N for Other Indications | 50% PS in US | |||||||
36 | Tag | Out | Licensor | Any | royalty reduced 4x (1 - actual co-dev/co-dev cap) | 10/2010 | Amicus Therapeutics | GlaxoSmithKline | Top Pharma | Phase III, Orphan Indication | FOIA | 30.00 | 234.00 | 19.00 | Deal | Worldwide | Amigal (migalastat) for Fabry disease | Co-Development, Equity, License, Supply, Termination | Endocrinological & Metabolic | Lysosomal Storage Disorders | Synthetics | Small Molecule | 31.00 | 0.30 | 93.50 | 154.50 | 80.00 | 16.50 | 18.00 | 18.50 | $31M equity (19.9% OS @ 30% premium to FMV - see separate agmt) | 14-19% royalty, subject to reduction of 4x ratio of actual co-dev cost vs. total co-dev cap, if Amicus opts out of co-dev | ||||||||
37 | Tag | Out | Licensor | Any | 14-24% royalty, depending on stage & sales | 1/2009 | ZymoGenetics | Bristol-Myers Squibb | Top Pharma | Phase I | FOIA | 105.00 | 1,106.50 | 40.00 | Deal | Worldwide | PEG-IFN Lambda for HCV | Co-Development, Co-Promotion, License, Option | Infectious-Viral | Hepatitis C | Drug Delivery, Peptides, Recombinant DNA | PEG Products | 0.26 | 430.00 | 286.50 | 821.50 | 285.00 | 14.00 | 14.50 | 16.25 | 40.00 | 14-20% royalty in ROW (max 24% in US if Opt-out after unblinding first Ph III) | $430M for HCV | $286.5M for HBV plus non-Hepatitis indications | 40% US PS if co-dev | |||||||
38 | Tag | Out | Licensor | Filing | 8-12% royalty & milestones, based on stage & sales | 1/2009 | Alnylam | Merck, Cubist | Top Pharma | Phase II | FOIA | 20.00 | 102.50 | 50.00 | Deal | Africa, Europe, Middle East, NAFTA, South America | ALN-RSV01 for respiratory syncytial virus infections ex-Asia | Co-Development, License, Supply, Termination | Infectious-Viral | Respiratory Syncytial Virus/RSV | Oligonucleotides | RNAi | 0.36 | 30.00 | 22.50 | 72.50 | 30.00 | 10.50 | 12.20 | 13.90 | 50.00 | 10-16% royalty ex-NAFTA | 50% PS in NAFTA | |||||||
39 | Tag | Out | Licensor | Filing | 16-23% royalty, depending on sales & dev costs | 12/2008 | Exelixis | Bristol-Myers Squibb | Top Pharma | Phase III, Phase I | FOIA | 240.00 | 1,100.00 | 50.00 | Deal | Worldwide | Cabozantinib (XL184 MET, VEGFR2, RET inhib) & XL281 (RAF kinase inhib) for thyroid & solid tumors | Co-Development, Co-Promotion, Development, License, Termination | Cancer | Other Cancer, Solid Tumors | Synthetics | Small Molecule | 0.26 | 30.00 | 530.00 | 800.00 | 300.00 | 14.00 | 14.00 | 15.00 | 50.00 | $195M on signing & $45M in 2009 | $150M in sales milestones for each product | $30M for XL184 for thyroid cancer | $315M in dev/reg milestones for XL281; $130M for XL184 in major tumor & $135M in glioblastoma | 50/50 US PS for XL184 if EXEL co-develops | 14-18% ex-US for XL184; 12-16% for XL281 | |||||||
40 | Tag | Out | Licensor | Any | 4-14% royalty, depending on stage, product & sales | 8/2008 | Facet, Abbott, PDL BioPharma | Bristol-Myers Squibb | Top Pharma | Phase I | FOIA | 30.00 | 1,155.00 | 30.00 | Deal | Worldwide | Elotuzumab (HuLuc63 CS1 Mab) for multiple myeloma & option for PDL-241 | Co-Development, License, Option | Cancer | Multiple Myeloma | Monoclonals | Humanized Abs | 0.26 | 260.00 | 465.00 | 755.00 | 400.00 | 13.00 | 13.00 | 13.50 | 30.00 | $200M in sales milestones for each compound | 13-16% ex-US royalty for HuLuc63; 12-14% ex-US royalty for Other Products | $260M for MM | $110M for each of 2nd & 3rd indication for HuLuc63; $15M on PDL-241 option exercise, $110M for PDL-241 1st indication, plus $60M for each of 2nd & 3rd indication | 30% PS to PDL in US | |||||||
41 | Tag | Out | Licensor | Filing | All Products: 18-24% royalty, depending on sales | 10/2007 | Madrigal Pharmaceuticals, Synta Pharmaceuticals | GlaxoSmithKline | Top Pharma | Phase II | FOIA | 80.00 | 1,010.00 | 50.00 | Deal | Worldwide | Elesclomol (STA-4783 oxidative stress inducer to trigger apoptosis) for melanoma | Co-Development, Co-Promotion, Equity, License, Termination | Cancer | Melanoma | Synthetics | Small Molecule | 45.00 | 0.25 | 135.00 | 450.00 | 710.00 | 300.00 | 16.00 | 16.00 | 17.50 | 50.00 | $45M in aggregate put equity at two milestones for 125% FMV | 16-22% royalty in ROW | 40% PS in US for first $500M, then 50/50 PS thereafter | ||||||
42 | Tag | Out | Licensor | Phase IIb data | New Indications: recoup costs lower PS & milestones | 10/2007 | Madrigal Pharmaceuticals, Synta Pharmaceuticals | GlaxoSmithKline | Top Pharma | Phase II | FOIA | 80.00 | 1,010.00 | 50.00 | Deal | Worldwide | Elesclomol (STA-4783 oxidative stress inducer to trigger apoptosis) for melanoma | Co-Development, Co-Promotion, Equity, License, Termination | Cancer | Melanoma | Synthetics | Small Molecule | 45.00 | 0.25 | 135.00 | 450.00 | 710.00 | 300.00 | 16.00 | 16.00 | 17.50 | 50.00 | $45M in aggregate put equity at two milestones for 125% FMV | 16-22% royalty in ROW | 40% PS in US for first $500M, then 50/50 PS thereafter | ||||||
43 | Tag | Out | Licensor | Filing | 30% PS in Shared Territory | 8/2007 | Nektar Therapeutics, Aerogen | Bayer | Top Pharma | Phase II, Formulation | FOIA | 50.00 | 175.00 | 30.00 | Deal | Worldwide | BAY41-6551 (NKTR-061, inhaled amikacin) for gram-negative pneumonias | Co-Development, Co-Promotion, License, Supply, Termination | Infectious-Bacterial | Pneumonia | Drug Delivery, Synthetics | Other, Small Molecule | 70.00 | 120.00 | 55.00 | 14.25 | 22.20 | 26.10 | 30.00 | 48.00 | 14-30% in ROW; also 30% in US if opt-out of PS | 48% PS to Nektar in US (eliminated per 12/10 am) | Supply by Nektar dropped per 12/10 am | ||||||||
44 | Tag | Out | Licensor | Any | 13-29% royalty, depending on stage | 12/2005 | Maxygen | Roche | Top Pharma | Preclinical | FOIA | 8.00 | 104.00 | 37.00 | Deal | Worldwide | MAXY_VII (recombinant factor VIIa) for acute bleeding indications | Co-Development, License, Option, Termination | Hematologic | Other Hematologic | Recombinant DNA | 0.35 | 52.00 | 44.00 | 104.00 | 27.60 | 30.00 | 33.25 | 27-37% in US; 20-30% in ROW | ||||||||||
45 | Tag | Out | Licensor | Any | pre-opt-out co-dev reimb via sales milestones | 12/2004 | Amgen, Micromet | Merck Serono, Serono | Top Pharma | Phase II | FOIA | 10.00 | 148.00 | 15.00 | Deal | Worldwide | MT201 (adecatumumab) anti EpCAM human monoclonal for cancer | Co-Development, Co-Promotion, License, Option | Cancer | Breast, Prostate | Monoclonals | Human Abs | 0.20 | 84.00 | 54.00 | 148.00 | 8.00 | 8.50 | 9.25 | 50.00 | royalty is in addition to any profit split for co-co dev | 50% PS if co-dev & co-promote in US and/or EU | ||||||||
46 | Tag | Out | Licensor | Phase IIb data | 13.25-17% royalties | 11/2004 | Medarex | Bristol-Myers Squibb | Top Pharma | Phase III | FOIA | 25.00 | 223.75 | 45.00 | Deal | Worldwide | Yervoy (ipilimumab MDX-010 huMAb to CTLA-4) & MDX-1379 (gp-100) for melanoma | Co-Development, Co-Promotion, Equity, License, Option | Cancer | Melanoma | Monoclonals | Human Abs | 60.00 | 58.75 | 143.75 | 55.00 | 10.50 | 12.60 | 13.80 | 45.00 | US PS if Co-Promotes | 15% max royalty for ex-US | ||||||||
47 | Tag | Out | Licensor | Any | 4-8% royalty in NAFTA vs. 50% PS | 6/2002 | Amgen, Tularik | Daiichi Sankyo, Sankyo | Japanese Pharma | Discovery | FOIA | 2.00 | 81.25 | 50.00 | Deal | Worldwide | Screening of 5 orphan GPCR drug targets | Co-Development, Co-Promotion, License, Research | Unlimited | Screening, Synthetics | Small Molecule | 14.75 | 0.28 | 19.50 | 36.25 | 45.00 | 4.00 | 5.00 | 5.50 | 50.00 | 4-8% royalty ex-NAFTA | 50% split of Distributable Margin in NAFTA | ||||||||
48 | Tag | Out | Licensor | Filing | subsequent milestones plus 5-12% royalty | 2/2002 | Ligand, Pharmacopeia | Schering-Plough, Merck, Organon | Top Pharma | Discovery | FOIA | 15.00 | 95.25 | 12.00 | Deal | Worldwide | Discovery of drug candidates | Co-Development, Co-Promotion, License, Option, Research | Unlimited | Screening, Synthetics | Combinatorial | 5.00 | 20.00 | 0.29 | 29.00 | 8.75 | 77.75 | 17.50 | 5.50 | 5.80 | 6.40 | 35.00 | $15M on restatement date | $5M equity put by Pharmacopeia | $4M/yr for 5 yrs | $162/Manhour x1800 hours | 5-12% if Lead Optimized; otherwise 3-5% | 35% co-co option for 35% PS | ||||||
49 | Tag | Out/In | Either party | Any | 200% of share of dev costs | 6/2011 | Meda AB | Bausch Health | Mid Tier Pharma | Approved | FOIA | 76.00 | Deal | NAFTA | Elidel (pimecrolimus 1% cream) and Xerese (acyclovir and hydrocortisone cream) for derm in NAFTA | License | Dermatologic | Broad Focus Dermatologic | 16.00 | 92.00 | 22% royalty for 2011, declining to 18% in 2012 then 10% thereafter | ||||||||||||||||||
50 | Tag | Out/In | Either party | Filing | 65% of dev costs | 12/2010 | Xoma | Servier | Mid Tier Pharma | Phase II | FOIA | 15.00 | 738.00 | 19.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Xoma 052 (gevokizumab) anti-IL1 beta mAb for diabetes and cardio ex-US & Japan | Co-Development, License, Loan, Supply, Termination | Autoimmune/Inflammatory, Cancer, Cardiovascular, Endocrinological & Metabolic, Ophthalmic | Broad Focus Cancer, Broad Focus Cardiovascular, Diabetes, Other Autoimmune/Inflammatory, Uveitis | Monoclonals | Humanized Abs | 50.00 | 18.00 | 68.00 | 262.00 | 413.00 | 325.00 | 10.00 | 10.40 | 11.10 | 10.00 | $325M or $186M (155M Euros) if Xoma keeps diabetes for US/Japan | 10% EFR in US/Japan if Retained Territory released by Xoma | 10.4% EFR in US/Japan if Retained Territory released by Xoma | 11.1% EFR in US/Japan if Retained Territory released by Xoma | 19% max royalty, based on Daily Cost of Treatment and COGS as function of Sales price | 15M Euros | $325M precomm'l payments if Xoma keeps diabetes in US/Japan; otherwise $413M | $20M US plus 40M Euros | $174M plus add'l $88M if Xoma drops co-dev | ||||||
51 | Tag | Out/In | Either party | Phase II data | 150% of dev costs (internal & out-of-pocket) | 6/2010 | Shire, Dyax | Leadiant Biosciences, Defiante | Mid Tier Pharma | Phase III | FOIA | 2.50 | 112.50 | 41.00 | Deal | Africa, Europe, Middle East | Kalbitor (DX-88 ecallantide) for hereditary angioedema (HAE) in Europe, Mideast & Africa | Co-Development, Equity, License, Supply, Termination | Autoimmune/Inflammatory | Other Autoimmune/Inflammatory | Synthetics | Small Molecule | 2.50 | 10.00 | 15.00 | 97.50 | 41.00 | ||||||||||||
52 | Tag | Out/In | Either party | Phase III data | 200% of share of dev cost (250% if first Ph III data) | 10/2009 | Bristol-Myers Squibb, Amylin | Takeda | Top Pharma | Phase II, Discovery | FOIA | 75.00 | 1,320.00 | 30.00 | Deal | Worldwide | Pramlintide/metreleptin and davalintide for treatment of obesity | Co-Development, Co-Promotion, License, Supply, Termination | Endocrinological & Metabolic | Obesity | Peptides | 0.30 | 115.00 | 330.00 | 520.00 | 800.00 | 15.00 | 15.00 | 17.50 | ||||||||||
53 | Tag | Out/In | Either party | Filing | 105-120% cost plus interest, depending on stage | 8/2008 | Bausch Health | GlaxoSmithKline | Top Pharma | Phase III, Orphan Indication | FOIA | 125.00 | 820.00 | 50.00 | Deal | Worldwide | Retigabine (KCNQ2/3 receptor potassium channel modulator) for epilepsy | Co-Development, Co-Promotion, License | Central Nervous System | Epilepsy | Synthetics | Small Molecule | 135.00 | 420.00 | 680.00 | 140.00 | 15.00 | 18.00 | 19.00 | 50.00 | ROW royalty: 15-20% for Retigabine; 10-20% for Add'l Product | $135M for Epilepsy | $90M for each of 3 Non-Epilepsy Indications, plus $150M for first Additional Product | 50% PS in NA & Oceania for immediate release product; 30-50% for modified release product, depending on year and sales level | ||||||||
54 | Tag | Out/In | Either party | Phase II data | 2x dev cost if Merck opt-in; 100% dev cost if GTx | 11/2007 | Oncternal Therapeutics, GTx | Merck | Top Pharma | Phase II, Preclinical, Lead Molecule | FOIA | 40.00 | 592.00 | 23.00 | Deal | Worldwide | Ostarine (selective androgen receptor modulator) for cancer-related muscle loss | Co-Development, Co-Promotion, Equity, License, Research, Termination | Cancer, Endocrinological & Metabolic | Other Cancer, Other Endocrinological & Metabolic | Synthetics | Small Molecule | 30.00 | 15.00 | 60.00 | 447.00 | 592.00 | 13.00 | 13.00 | 13.00 | 1.285M common shares @ $23.34/sh (see Equity agmt) | $5M in R&D funding/yr for 3 yrs | $60M for Ostarine for Cancer Cachexia | $220M for sarcopenia; $142M add'l for cancer cachexia; $85M for any other indication | ||||||||
55 | Tag | Out/In | Either party | Phase IIb data | 100% of development costs | 11/2007 | Amicus Therapeutics | Takeda, Shire | Major Biotech, Top Pharma | Phase II, Orphan Indication | FOIA | 50.00 | 440.00 | 22.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Plicera for Gaucher, Amigal for Fabry & AT2220 for Pompe genetic disorders ex-US | Co-Development, License, Option, Termination | Endocrinological & Metabolic, Other/Miscellaneous | Genetic Disorders, Lysosomal Storage Disorders | Synthetics | Small Molecule | 60.75 | 0.25 | 150.00 | 260.75 | 240.00 | 11.50 | 12.75 | 14.88 | 50/50 sharing of $121.5M budgeted dev costs over 3 yrs | ||||||||
56 | Tag | Out/In | Either party | Phase III done | 100% cost plus 25% compounded annual interest | 9/2007 | Shire, NPS Pharmaceuticals | Takeda, Nycomed Pharma | Top Pharma | Phase III | FOIA | 10.00 | 225.00 | 18.00 | Deal | Africa, Asia, Europe, Middle East, South America | Gattex/Revestive (teduglutide GLP-2) for short bowel syndrome and GI ex-NAFTA | Co-Development, License, Termination | Gastrointestinal | Bowel Movement Disorders, Other Gastrointestinal | Peptides | 0.28 | 50.00 | 145.00 | 205.00 | 20.00 | 18.00 | 18.00 | 18.00 | $50M for SBS | |||||||||
57 | Tag | Out/In | Either party | Filing | 50% of dev costs plus 100% of share of dev costs | 6/2007 | Bristol-Myers Squibb, ZymoGenetics | Bayer | Top Pharma | Filed | FOIA | 30.00 | 158.00 | 20.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Recothrom (rThrombin) for hemostasis ex-US | Co-Development, License | Hematologic | Other Hematologic | Recombinant DNA | 23.00 | 53.00 | 105.00 | 13.50 | 16.00 | 18.20 | 18.00 | 15-20% sales commission to Bayer on US co-promotion (see separate analysis) | $23M in ex-US milestones, plus add'l $40M on US approval (see separate analysis) | ||||||||||
58 | Tag | Out/In | Either party | Any | 100-200% of cost share, depending on stage | 9/2006 | Oncternal Therapeutics, GTx | Ipsen | Mid Tier Pharma | Phase III | FOIA | 30.00 | 74.20 | 25.00 | Deal | Europe | Acapodene (toremifene) for treatment of prostate cancer & prevention of fractures in Europe | Co-Development, License, Supply, Termination | Bone Disease, Cancer | Other Bone Disease, Prostate | Synthetics | Small Molecule | 0.23 | 11.70 | 32.50 | 74.20 | 30.00 | 23M Euros | royalty rate is 30% minus cost of supply; min of 14.5% for PIN, 13% for ADT Indication | 9M Euros for ADT | 25M Euros for PIN | |||||||||||
59 | Tag | Out/In | Either party | Phase II data | 50% of dev costs (FTE & direct out-of-pocket) | 8/2006 | Human Genome Sciences | GlaxoSmithKline | Top Pharma | Lead Molecule | FOIA | 24.00 | 24.00 | 50.00 | Deal | Worldwide | Benlysta (belimumab hMAb to BLyS) to treat lupus | Co-Development, Co-Promotion, License, Supply | Autoimmune/Inflammatory | Systemic Lupus Erythematosus | Monoclonals | Human Abs | 24.00 | 50.00 | |||||||||||||||
60 | Tag | Out/In | Either party | Any | 30% of share of dev costs | 1/2006 | ARCA Biopharma | Bayer | Top Pharma | Phase III | FOIA | 50.00 | 385.00 | 37.50 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Alfimeprase for peripheral arterial occlusions ex-US | Co-Development, License, Termination | Cardiovascular | Peripheral Arterial Disease | Recombinant DNA | 0.30 | 75.00 | 90.00 | 215.00 | 170.00 | 17.50 | 23.00 | 27.75 | 15.00 | |||||||||
61 | Tag | Out/In | Either party | Any | 2x share of development costs | 12/2005 | Agennix, GPC Biotech | Celgene, Pharmion | Major Biotech | Phase III | FOIA | 37.10 | 247.60 | 34.00 | Deal | Asia, Europe, Middle East | Satraplatin for prostate cancer in Europe, Mideast, Australia & New Zealand | Co-Development, License, Supply | Cancer | Prostate | Natural Product | 0.26 | 30.50 | 75.00 | 142.60 | 105.00 | 27.00 | 29.00 | 31.44 | 10.00 | |||||||||
62 | Tag | Out/In | Either party | Phase IIb data | 200% of share of dev cost | 9/2005 | Facet, Abbott, AbbVie, PDL BioPharma | Biogen | Major Biotech | Phase II, Orphan Indication | FOIA | 40.00 | 520.00 | 50.00 | Deal | Worldwide | Zinbryta (daclizumab) for multiple sclerosis, M200 (volociximab) & HuZAF (fontolizumab) | Co-Development, Co-Promotion, Equity, License, Supply | Autoimmune/Inflammatory, Cancer, Central Nervous System | Broad Focus Autoimmune/Inflammatory, Multiple Sclerosis, Solid Tumors | Monoclonals | Humanized Abs | 5.00 | 0.25 | 85.00 | 240.00 | 370.00 | 50.00 | 12.00 | 13.60 | 16.80 | 15.00 | 50.00 | $85M in dev/reg milestones for IL-2R or INFy for 1st indication | $80M for each of 2nd & 3rd IL-2R or INFy indications, plus $40M for each of 2nd &3rd A5B1 indications | 50/50 PS in NA and EU | ROW Royalty of 12-20% | |||||
63 | Tag | Out/In | Either party | Any | 75% dev cost b4 first Ph III data; 100% if later | 5/2005 | BioMarin | Merck Serono, Serono | Top Pharma | Phase III, Preclinical, Orphan Indication | FOIA | 25.00 | 257.00 | 18.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Kuvan (sapropterin dihydrochloride) and Phenylase (phenylalanine ammonia lyase) ex-NA & Japan | Co-Development, License, Supply, Termination | Endocrinological & Metabolic | Other Endocrinological & Metabolic | Recombinant DNA, Synthetics | Small Molecule | 45.00 | 187.00 | 257.00 | 11.50 | 14.20 | 16.10 | |||||||||||
64 | Tag | Out/In | Either party | 1 yr from Opt-out | 2-3.5x share of dev cost, depending on stage | 3/2005 | ARCA Biopharma | Kirin | Japanese Pharma | Preclinical, Discovery | FOIA | 2.00 | 2.00 | 60.00 | Deal | Worldwide | NU206 growth factor for radiation-induced mucositis and IBD | Co-Development, License, Supply | Dental/Oral, Gastrointestinal | IBD - Other, Mucositis | Recombinant DNA | 0.25 | 2.00 | 10.00 | 60.00 | 2-9.975% royalty after opt-out, depending on stage and which party opts out | |||||||||||||
65 | Tag | Out/In | Either party | Phase IIb data | 75% of dev costs or 100% if approved | 1/2005 | New River Pharmaceuticals | Takeda, Shire | Major Biotech, Top Pharma | Phase III | FOIA | 50.00 | 505.00 | 50.00 | Deal | Worldwide | Vyvanse (NRP104 lisdexamfetamine dimesylate) for ADHD | Co-Development, Co-Promotion, License, Supply | Psychiatric | Attention Deficit Hyperactivity Disorder | 355.00 | 405.00 | 100.00 | 12.00 | 13.20 | 14.60 | 20.00 | 50.00 | 12-16% in Major EU; 12% in ROW except for Major EU and US | COGS +20% | US profit split of 25% to New River for first two years, then 50% thereafter | ||||||||||
66 | Tag | Out/In | Either party | Phase II data | 250% of dev costs | 9/2004 | Xoma | Aphton | Other Biotech | Discovery | FOIA | 30.00 | Deal | Worldwide | Anti-gastrin monoclonal antibodies | Co-Development, Co-Promotion, License, Option, Supply | Cancer | Colorectal, Other Cancer | Monoclonals | Human Abs | 0.33 | 30.00 | |||||||||||||||||
67 | Tag | Out/In | Either party | Phase III data | 62.5% dev cost (Ph II) or 75% (Ph III) | 4/2004 | Genentech | Roche | Top Pharma | Discovery | SEC Full | 50.00 | Deal | Worldwide | Joint research in oncology, immunology and protein therapeutics | Co-Development, Co-Promotion, License, Option, Research, Supply | Autoimmune/Inflammatory, Cancer | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer | Recombinant DNA, Synthetics | Small Molecule | 20.00 | 50.00 | |||||||||||||||||
68 | Tag | Out/In | Either party | Phase III data | 150% dev cost (plus 5% royalty if Ph III) | 9/2002 | Bristol-Myers Squibb, Amylin | Lilly | Top Pharma | Phase III | FOIA | 80.00 | 555.00 | 50.00 | Deal | Worldwide | BYETTA (exenatide) GLP-1 for type 2 diabetes | Co-Development, Co-Promotion, Equity, License, Loan, Option, Supply, Termination | Endocrinological & Metabolic | Diabetes | Synthetics | Small Molecule | 30.00 | 110.00 | 0.27 | 110.00 | 155.00 | 70.00 | 555.00 | 50.00 | $70M on SR Product launch | $60M development and $50M commercialization credit facilities | 50/50 in US; 80/20 in favor of Lilly ex-US up to $1B/yr, then 75/25 in favor of LIlly ex-US | ||||||||
69 | Tag | Out/In | Either party | Phase I data | 200% of internal and out-of-pocket costs | 4/2002 | Genta | Sanofi, Aventis | Top Pharma | Phase III | FOIA | 50.00 | 405.00 | 28.00 | Deal | Worldwide | Genasense (G3139 BCL-2 downregulator) for cancer | Co-Development, Co-Promotion, Equity, License, Loan, Supply | Cancer | Broad Focus Cancer | Oligonucleotides | Antisense/Triple helix | 0.22 | 75.00 | 195.00 | 85.00 | 405.00 | 20.00 | 20.40 | 21.80 | US: 15% on first $300M in cum US sales, then 20-28% royalty on annual US sales; ROW is 15-19% royalty (see separate contract | $75M convertible note (w/ conversion at 425th patient in Ph III trial) | ||||||||
70 | Tag | Out/In | Either party | Phase IIb data | Reimb 75% of out-of-pocket dev costs | 4/1998 | Johnson & Johnson, Centocor | Merck, Schering-Plough | Top Pharma | Phase III | FOIA | 20.00 | 62.00 | 40.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Remicade (chimeric Anti-TNF antibody) for RA and IBD ex-US, Japan, China and Indonesia | Co-Development, Co-Promotion, Distribution, Option | Autoimmune/Inflammatory, Gastrointestinal | IBD - Crohn's Disease, IBD - Other, IBD - Ulcerative Colitis, Rheumatoid Arthritis | Monoclonals | Humanized Abs | 12.00 | 10.00 | 20.00 | 62.00 | 40.00 | $10M for Crohn's | 32% to $150M, then 40% > $150M/yr | |||||||||||
71 | Tag | Out/In | Either party | Any | 10% interest on share thru I; 20% if later | 1/1998 | Lundbeck A/S, Synaptic | Grunenthal | Mid Tier Pharma | Discovery | FOIA | 4.00 | Deal | Europe, South America | Targeting alpha-2 adrenergic receptors to treat pain in Europe and S America | Co-Development, License, Research | Central Nervous System | Pain | Recombinant DNA | 4.00 | 4.00 | 4.00 | |||||||||||||||||
72 | Tag | Out/In | Either party | Filing | 100% of Ph II or 125% of Ph III dev costs | 2/1997 | Transcend Therapeutics | Boehringer Ingelheim | Mid Tier Pharma | Phase III | FOIA | 5.00 | 46.00 | 25.00 | Deal | Worldwide | Procysteine (glutathione-repleting agent) for Acute Respiratory Distress Syndrome (ARDS) | Co-Development, Co-Promotion, License, Supply, Termination | Respiratory | Acute Respiratory Distress Syndrome | 5.00 | 13.00 | 23.00 | 46.00 | 25.00 | 25.00 | 25.00 | 7.00 | 25% in US, 10% in Japan, 15% in ROW | 7% of Net Sales cap on Manu Cost (plus royalty) | ||||||||||
73 | Tag | Out/In | Either party | Filing | 10% interest on share thru II; 30% if Ph III | 5/1995 | IDM Pharma, Takeda, Epimmune | Schwarz Pharma | Mid Tier Pharma | Phase II | FOIA | 2.00 | 18.50 | 50.00 | Deal | Europe, NAFTA | Cylexin (CY 1503 selectin blocker) for lung injury and MI in NAFTA & Europe | Co-Development, Co-Promotion, Equity, License, Supply | Cardiovascular | Myocardial Infarction | Carbohydrates | 2.00 | 14.50 | 18.50 | 9.00 | 10.60 | 11.30 | 35.00 | 50.00 | 8-12% royalty in Europe if Cytel doesn't supply | 30-35% transfer price in Europe | 50% PS from co-promotion in NAFTA | |||||||||
74 | Tag | Out/In | Either party | Phase IIb data | Add'l 4% royalty to rejoin dev after opt-out | 5/1991 | Millennium, Takeda, COR Therapeutics | Lilly | Top Pharma | Lead Molecule, Discovery | FOIA | 8.95 | 50.00 | Deal | Worldwide | Platelet aggregation inhibitors (PAI) for cardiovascular | Co-Development, Co-Promotion, License, Option, Research | Cardiovascular | Broad Focus Cardiovascular | Peptides, Synthetics | Small Molecule | 7.70 | 1.25 | 8.95 | 50.00 | 7% royalty if no co-promotion | |||||||||||||
75 | Tag | Out/In | Licensee | Any | 3x option fee plus 4x dev cost incurred | 3/2013 | bluebird bio | Celgene | Major Biotech | Discovery | FOIA | 75.00 | 505.00 | 50.00 | Deal | Worldwide | Chimeric antigen receptor (CAR) T cell gene therapy for cancer | Co-Development, Co-Promotion, Equity, License, Loan, Option, Research | Cancer | Broad Focus Cancer | Cell Therapy - Stem Cells/Factors, Oligonucleotides | Gene Therapy | 20.00 | 0.33 | 100.00 | 165.00 | 145.00 | 505.00 | 6.00 | 7.50 | 8.75 | 5.00 | 50.00 | $20M or 9.9% OS in Bluebird IPO | 50/50 co-dev and PS option in US, w reduction in milestones to $70M for 1st, plus $40M for 2nd | Bluebird pays thru Ph I, then all by Celgene | $75M convertible Debt Financing for US Co-Dev; plus $25M non-convertible debt | $165M for 1st Indication | $80M in R&D Collaboration extension payments plus $65M for Second Indication | |||||
76 | Tag | Out/In | Licensee | Filing | 120% of dev costs, plus approval milestone | 9/2012 | Onconova | Baxalta, Shire, Baxter | Major Biotech, Top Pharma | Phase III | FOIA | 50.00 | 887.50 | 21.00 | Deal | Europe, Middle East | Estybon (rigosertib multi-kinase inhibitor) for MDS and pancreatic cancer in Europe & Turkey | Co-Development, Equity, License, Option, Termination | Cancer | Leukemia, Pancreatic | Synthetics | Small Molecule | 50.00 | 5.00 | 207.50 | 325.00 | 637.50 | 250.00 | 13.00 | 14.50 | 16.75 | $50M in preferred equity 7/12, per Onconova's 2014 10-K | $5M at IPO, per Onconova's 2014 10-K | $207.5M for MDS IV | $150M for MDS Oral, plus $175M for Pancreatic | |||||||
77 | Tag | Out/In | Licensee | Phase IIb data | 50% costs, plus add'l 15% costs going-forward | 9/2008 | Gilead, CV Therapeutics | Menarini | Mid Tier Pharma | Approved, Formulation | FOIA | 70.00 | 285.00 | 33.00 | Deal | Europe, South America | Renexa (ranolazine SR) for angina in Europe and S. America | Co-Development, Co-Promotion, License, Supply | Cardiovascular | Angina | Drug Delivery, Synthetics | Small Molecule, Sustained Release | 0.35 | 10.00 | 80.00 | 160.00 | 125.00 | 22.00 | 25.50 | 29.25 | 10.00 | 88.4M Euros | |||||||
78 | Tag | Out/In | Licensee | Filing | $20M, 115% costs, $55M milestones & +4% royalty | 6/2008 | rEVO Biologics | Lundbeck A/S, Ovation Pharma | Mid Tier Pharma | Filed | FOIA | 3.00 | 231.50 | 16.00 | Deal | NAFTA | Recombinant antithrombin alfa for thromboembolic events in US | Co-Development, License, Supply | Cardiovascular | Other Cardiovascular | Recombinant DNA, Transgenics | 10.00 | 6.00 | 57.50 | 76.50 | 155.00 | 13.63 | 15.05 | 15.53 | $10M for HR Indication dev | $6M for HD Indication | $17.5M for HR Indication, plus $40M for DIC/Sepsis Indication | |||||||||
79 | Tag | Out/In | Licensee | Phase II data | 150% cost if IND tox; 300% cost if first Ph II | 10/2006 | InterMune | Roche | Top Pharma | Preclinical | FOIA | 60.00 | 560.00 | 19.00 | Deal | Worldwide | Danoprevir (ITMN-191) cyclic macrocycle for HCV | Co-Development, Co-Promotion, License, Termination | Infectious-Viral | Hepatitis C | Peptides | 250.00 | 310.00 | 240.00 | 14.00 | 15.00 | 17.00 | 50.00 | |||||||||||
80 | Tag | Out/In | Licensee | Phase II data | return to base milestone/royalty terms | 3/2006 | Merck, Alnylam, Sirna Therapeutics | GlaxoSmithKline | Top Pharma | Discovery | FOIA | 6.00 | 99.50 | 8.00 | Deal | Worldwide | siRNA therapeutics for PDE4A, PDE4B & RSV respiratory targets | Equity, License, Research | Infectious-Viral, Respiratory | Broad Focus Respiratory, Respiratory Syncytial Virus/RSV | Oligonucleotides | RNAi | 6.00 | 47.50 | 40.00 | 99.50 | 6.00 | 6.00 | 7.00 | $6M eq at 25% premium | $3-5M Target Expansion Fee, plus $17.5M for each of 2nd and 3rd indications | |||||||||
81 | Tag | Out/In | Licensee | Phase III data | 2x cost if Ph II; 3x thru II & 2x add'l if III | 12/2004 | Amgen, Micromet | Merck Serono, Serono | Top Pharma | Phase II | FOIA | 10.00 | 148.00 | 15.00 | Deal | Worldwide | MT201 (adecatumumab) anti EpCAM human monoclonal for cancer | Co-Development, Co-Promotion, License, Option | Cancer | Breast, Prostate | Monoclonals | Human Abs | 0.20 | 84.00 | 54.00 | 148.00 | 8.00 | 8.50 | 9.25 | 50.00 | royalty is in addition to any profit split for co-co dev | 50% PS if co-dev & co-promote in US and/or EU | ||||||||
82 | Tag | Out/In | Licensee | Any | 45% (3 yr) or 80% dev cost reimb | 6/2003 | Takeda, Millennium | Johnson & Johnson, Ortho Biotech | Top Pharma | Filed | FOIA | 15.00 | 505.00 | 24.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | VELCADE (bortezomib) for myeloma ex-US | Co-Development, Co-Promotion, License, Option, Supply | Cancer | Broad Focus Cancer, Multiple Myeloma | Synthetics | Small Molecule | 0.28 | 75.00 | 300.00 | 390.00 | 115.00 | 13.00 | 14.80 | 18.20 | 15.00 | ||||||||
83 | Tag | Out/In | Licensee | Phase IIb data | 150% of option exercise amt ($35-75M) | 10/2002 | Exelixis | GlaxoSmithKline | Top Pharma | Discovery | FOIA | 30.00 | 614.00 | 17.00 | Deal | Worldwide | Chk1, SS-RTK, ADAM10 & Dual KDR/FGFR1 inhibitor targets for cancer, cardio & inflammation | Co-Development, Co-Promotion, Equity, License, Loan, Option, Research, Termination | Autoimmune/Inflammatory, Cancer, Cardiovascular | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer, Broad Focus Cardiovascular | Genomics, Synthetics | Gene Expression, Small Molecule | 14.00 | 30.00 | 90.00 | 85.00 | 165.00 | 150.00 | 564.00 | 50.00 | 10.00 | 10.00 | 10.75 | $14M (2M @ $7/sh) in initial equity @ 100% premium per 10/28/02 PR | $30M add'l put equity @ 125% of FMV if GSK Expands Program | $90M over 6 yrs | 10-13% for 1st product (increasing for add'l products, up to 13-17% for 5 products) | $85M loan facility (increasing to $300M if GSK Expands Program) | $35-75M for 1st Compound, depending when accepted by GSK | $20M on Expanded Option exercise, $40M in Expanded Option payments plus add'l $90M in R&D funding | |||||
84 | Tag | Out/In | Licensee | Phase IIb data | 125% share of dev cost (direct & indirect) | 8/1998 | Vertex | Bayer, Schering AG | Top Pharma | Preclinical, Lead Molecule | FOIA | 6.00 | 87.50 | 30.00 | Deal | Worldwide | VX-853 & orally active neurophilin compounds for neurological diseases | Co-Development, Co-Promotion, License, Research, Supply | Central Nervous System | Broad Focus Central Nervous System | Synthetics | Small Molecule | 22.00 | 25.00 | 34.50 | 87.50 | 15.00 | 15.00 | 15.00 | 30.00 | $25M for VX-853 | 25-30% transfer price, depending on annual sales | $17.25M in milestones for other compounds, 2x max | ||||||||
85 | Tag | Out/In | Licensee | Phase IIb data | 150% share to IND; 200% if pre-II or 250% | 10/1995 | Purdue Pharma, CoCensys | Pfizer, Warner-Lambert | Top Pharma | Lead Molecule, Discovery | FOIA | 25.70 | 9.00 | Deal | Worldwide | NMDA receptor subtype antagonists for CNS diseases | Co-Promotion, Development, Equity, License, Option, Research | Central Nervous System | Broad Focus Central Nervous System | Screening, Synthetics | Small Molecule | 7.00 | 2.20 | 0.22 | 11.50 | 5.00 | 25.70 | 6.00 | 6.00 | 6.75 | 25.00 | 9% of Net Sales if Co-Promote in US | 15-25% PS if CoCensys elects to codev | |||||||
86 | Tag | Out/In | Licensee | IND | 2x dev costs incurred (FTE & external) | 5/1995 | Amgen, Onyx Pharmaceuticals | Pfizer, Warner-Lambert | Top Pharma | Lead Molecule | FOIA | 30.20 | 8.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | Ibrance (Palbociclib PD-0332991 CDK4 inhibitor) for breast cancer ex-Japan | Co-Promotion, Equity, License, Research, Restatement | Cancer | Breast | Screening, Transcription Factors | 7.00 | 6.20 | 8.50 | 8.50 | 30.20 | 8.00 | 8.00 | 8.00 | |||||||||||
87 | Tag | In | Either party | Phase II data | 45-200% dev cost, depending on party & stage | 6/2015 | Juno Therapeutics | Celgene | Major Biotech | Phase II | FOIA | 150.20 | 1,150.20 | 50.00 | Deal | Worldwide | CAR-T and TCR technologies for cancer and autoimmune diseases | Co-Development, Co-Promotion, Equity, License, Option | Autoimmune/Inflammatory, Cancer | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer | Cell Therapy - Stem Cells/Factors | 850.00 | 150.00 | 1,100.00 | 50.00 | 9.1M shares @ $93/sh | Celgene has contingent rights to purchase up to 30% OS of Juno, per Celgene corp presentation | 50% PS on Juno originated programs (other than CD19 or CD22) & 30% PS globally on Celgene-originated programs | $50-75M on option exercise for each of CD19 & CD22 Program, depending on stage at exercise | |||||||||||||
88 | Tag | In | Licensee | Phase I data | $20M plus add'l 1% royalty | 3/2015 | Ziopharm, Intrexon | Merck KGaA, Merck Serono, Precigen | Top Pharma | Discovery | FOIA | 115.00 | 608.00 | 13.00 | Deal | Worldwide | Chimeric antigen receptor T-cell (CAR-T) products for cancer | Assignment, License, Option, Research, Supply | Cancer | Broad Focus Cancer | Cell Therapy - Stem Cells/Factors | 10.00 | 77.50 | 200.50 | 403.00 | 205.00 | 2.00 | 3.00 | 4.50 | $205M per Product | $10M for first two Targets, plus $5M for each add'l Target selected by Serono | $77.5M for 1st indication | $130.5M for add'l indications, plus $20M if Serono opts-in for Out-of-Scope Target; $40M for Allogeneic Cell Therapy entering Ph II or III using cells not from patients in trial; $10M on initiation of Ph III for solid tumor indication | |||||||||
89 | Tag | In | Licensee | Phase II data | $3-25M plus 50% cost, depending on stage & PS | 1/2015 | Agenus | Incyte | Major Biotech | Lead Molecule, Discovery | FOIA | 25.00 | 495.00 | 15.00 | Deal | Worldwide | Retrocyte Display platform to develop immuno-oncology antibodies targeting GITR, OX40, LAG-3 & TIM-3 | Co-Development, Co-Promotion, Equity, License, Option, Research | Cancer | Broad Focus Cancer | Monoclonals | Human Abs, Humanized Abs | 35.00 | 60.00 | 0.28 | 220.00 | 85.00 | 425.00 | 70.00 | 15.00 | 15.00 | 15.00 | Add'l 10M shares purchased 2/17 @ $6/sh, per Agenus' 9Q17 | 6-12% for Royalty-Bearing Products (TIM-3 & LAG-3); 15% royalty on GITR & OX-40 per 2/17 Amendment per Agenus' 9Q17 | 50/50 sharing of profits for the GITR and OX40 antibody programs, plus two of the add'l targets added in 11/15, per Agenus' 2016 10-K; PS eliminated per 2/17 Amendment per Agenus' 2016 10-K | $70M for Royalty-Bearing Products | Initially $20M for Profit-Share Products (GITR & OX-40); As of 2/17 Am, add'l milestones for GITR and OX-40 of $220M in aggregate, per Agenus' 9Q17 | $80M for each Royalty-Bearing Product | $490M (counting 2/17 add'l equity, and 1 Royalty-Bearing Product) | ||||||
90 | Tag | In | Licensee | Preclin tox | $7.5M plus 50% of dev costs (FTE & other) | 7/2006 | Alnylam | Merck | Top Pharma | Discovery | FOIA | 84.50 | 50.00 | Deal | Worldwide | RNAi for nine non-druggable targets | Co-Development, Co-Promotion, License, Option, Research, Restatement, Termination | Unlimited | Oligonucleotides | RNAi | 0.49 | 41.00 | 43.50 | 84.50 | 10.00 | 11.40 | 13.00 | 50.00 | 10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products | ||||||||||
91 | Tag | In | Licensee | Phase II data | $10M IND ($42M POC) exercise +$47M milestones | 12/2005 | Catalyst Biosciences, Targacept | AstraZeneca | Top Pharma | Phase II, Discovery | FOIA | 10.00 | 373.40 | 19.00 | Deal | Worldwide | Neuronal nicotinic receptors, including TC-1734 for Alzheimer's and cognitive dysfunction | Co-Promotion, Development, License, Option, Research, Termination | Central Nervous System, Psychiatric | Alzheimer's Disease, Schizophrenia | Synthetics | Small Molecule | 26.40 | 0.27 | 165.00 | 172.00 | 373.40 | 11.00 | 11.00 | 12.00 | $26.4M over 4 yrs | IND: $10M on Option Compound exercise, plus $75M dev/reg; POC: $42M on exercies, plus $130M dev/reg | ||||||||
92 | Tag | In | Licensee | Phase III done | terms TBD | 9/2004 | Merck KGaA | Clinical Data, Genaissance Pharmaceuticals | Other Biotech | Phase II | FOIA | 45.50 | 10.00 | Deal | Worldwide | Vilazodone (selective serotonin reuptake inhibitor (SSRI) & 5HT1A partial agonist) for depression | Co-Development, Co-Promotion, Equity, License, Option | Psychiatric | Depression & Mania | Synthetics | Small Molecule | 1.30 | 44.20 | 45.50 | 10.00 | 10.00 | 10.00 | 1M Euros of Genaissance equity | 34M Euros worth of equity for milestones | |||||||||||
93 | Tag | In | Licensee | Preclin tox | $7.5M plus 50% of dev costs (FTE & other) | 9/2003 | Alnylam | Merck | Top Pharma | Discovery | FOIA | 4.00 | 16.00 | 50.00 | Deal | Worldwide | RNAi technology for non-druggable targets | Co-Development, Co-Promotion, Equity, License, Option, Research, Termination | Unlimited | Oligonucleotides | RNAi | 5.00 | 5.00 | 2.00 | 16.00 | 10.00 | 11.40 | 13.00 | 50.00 | 10-15% ROW royalty for RNAi Products; 5-8% on Merck Products | 50/50 PS on Profit Sharing RNAi Products in US | |||||||||
94 | Tag | In | Licensee | IND | $1M plus 50% of fully burdened dev cost | 5/2001 | Exelixis | PDL BioPharma | Other Biotech | Discovery | FOIA | 44.50 | 40.00 | Deal | Worldwide | Humanized antibodies for cancer | Co-Development, License, Loan, Option, Research | Cancer | Broad Focus Cancer | Monoclonals | Humanized Abs | 8.00 | 30.00 | 6.50 | 44.50 | 7.00 | 7.00 | 7.00 | 40.00 | ||||||||||
95 | Tag | In | Licensee | Approval | 50% of Ph II & 75% of Ph III dev cost | 7/1999 | Genentech | Roche | Top Pharma | Approved, Orphan Indication | SEC Full | 1,900.00 | 20.00 | Deal | Worldwide | DNase/Pulmozyme drug and affiliation agreement | Development, Research | Respiratory | Cystic Fibrosis | Drug Delivery | Other | ||||||||||||||||||
96 | Tag | In | Licensee | IND | Reimb 300% dev costs (200% after Term) | 4/1994 | Amgen, Onyx Pharmaceuticals | Bayer | Top Pharma | Discovery | FOIA | 78.50 | 50.00 | Deal | Worldwide | Nexavar (sorafenib) oral Ras kinase inhibitor for liver & kidney cancer | Co-Development, Co-Promotion, Equity, License, Loan, Research, Settlement | Cancer | Kidney, Liver | Screening, Transcription Factors | 13.50 | 25.00 | 0.20 | 40.00 | 78.50 | 50.00 | 7% royalty for Japan & any co-dev opt-out countries | 50/50 PS in all co-dev countries (Onyx opted-out in Japan) | ||||||||||||
97 | Tag | In | Licensor | Phase II data | 65% cost (max $10M) at IND; 90% (max $25M) at II | 7/2007 | Roche, Genentech | Ipsen, Tercica | Mid Tier Pharma | Preclinical | FOIA | 18.00 | 12.00 | Deal | Worldwide | Growth hormone & IGF-1 combination product for short stature | Co-Development, Co-Promotion, Equity, License, Option | Endocrinological & Metabolic | Growth Hormone Disorders | Recombinant DNA | 4.00 | 9.00 | 5.00 | 18.00 | 12.00 | 12.00 | 12.00 | 25.00 | 50.00 | GNE purchases 708.6K Tercica shares | Add'l $4M eq purchase if GNE extends opt-in period, plus $5M eq at approval | 12% royalty to GNE if GNE never opts-in | 50/50 PS for Short Stature and AGHD Indications after GNE opt-in, but drops to 33.3% if GNE pays $10M to have tie-breaking vote | |||||||||
98 | Tag | In | Licensor | Phase IIb data | IL-1: $140M for 45% PS in NAFTA | 3/2003 | Regeneron Pharmaceuticals | Novartis | Top Pharma | Phase II | FOIA | 27.00 | 625.00 | 50.00 | Deal | Africa, Asia, Europe, Middle East, NAFTA, South America | IL-1 Trap for rheumatoid arthritis ex-Japan | Co-Development, Co-Market, Co-Promotion, Equity, License, Option | Autoimmune/Inflammatory | Rheumatoid Arthritis | Recombinant DNA | 48.00 | 0.30 | 50.00 | 125.00 | 500.00 | 50.00 | 50/50 PS for | |||||||||||
99 | Tag | In | Licensor | Phase IIb data | 35% US PS or 2% higher royalty | 4/2002 | Cubist, Merck, Adolor | GlaxoSmithKline | Top Pharma | Phase III | FOIA | 50.00 | 260.00 | 50.00 | Deal | Worldwide | Entereg (alvimopan mu receptor antag) for postop ileus, IBS and constipation | Co-Development, Co-Promotion, License, Supply, Termination | Gastrointestinal | Bowel Movement Disorders, IBD - Other, Other Gastrointestinal | Synthetics | Small Molecule | 50.00 | 160.00 | 260.00 | 20.00 | 20.00 | 20.00 | 50.00 | 18-20% royalty for Ex-US, depending on Product indication | $40M for IBS Product; $30M for each of Constipation & OBD Acute Products; $25M for OBD Chronic Product; $35M max for Add'l Products | 35-50% US PS, depending on years from launch and Product indication | |||||||||
100 | Tag | In | Licensor | Any | Fee TBD but 30% of cost attributed to US | 3/1995 | Biogen, IDEC | Roche, Genentech | Top Pharma | Phase II | FOIA | 4.00 | 56.50 | 40.00 | Deal | Worldwide | Rituxin (rituximab chimeric CD20 MAb) for non-Hodgkin's lymphoma and RA | Co-Development, Co-Promotion, Equity, License, Supply | Autoimmune/Inflammatory, Cancer | Leukemia, Lymphoma, Rheumatoid Arthritis | Monoclonals | 5.00 | 17.50 | 30.00 | 56.50 | 11.25 | 11.70 | 11.85 | 40.00 | $5M pref eq at 3/95 signing | 10-12% royalty ex-NA | 30% PS in NA up to $50M in Operating Profits, then 40% PS in NA above $50M/yr |